Monomethyl fumarate
How it works: Calming and slowing immune cells →
Bafiertam
EU: Approved nationally (not via EMA)US: FDA approved 2020
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- Kelch-like ECH-associated protein 1 inhibitor
- Targets
- Kelch-like ECH-associated protein 1
Approvals
- USBafiertam · Approved2020-04-28 Source
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
926 reports in total, 120 marked serious.
- Flushing348
- Pruritus110
- Product dose omission issue83
- Nausea75
- Abdominal discomfort65
- Erythema65
- Abdominal pain upper51
- Fatigue47
- Diarrhoea46
- Rash44
Trials
Other trials (5)
Completed small trials, dose-finding studies and trials in other diseases.
- SIMPLE
Terminated · Relapsing MS · stopped_other
- PERSIST
Withdrawn · Relapsing MS · stopped_other
- Monomethyl fumarate, phase 1
Completed · Phase 1 · Relapsing MS · no_result_found
- Monomethyl fumarate, phase 1
Completed · Phase 1 · MS (type not specified) · no_result_found
- Monomethyl fumarate, phase 1
Completed · Phase 1 · Relapsing MS · results_posted_no_test
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error